Guided Therapeutics Ships First Order of 10,000 LuViva® Advanced Cervical Scan Disposables for $14 Million Turkish Ministry of Health Order

Guided Therapeutics and FDA Review Team Agree on Path Forward for LuViva® Advanced Cervical Scan PMA Application

Guided Therapeutics to Present at LD Micro “Main Event” Investor Conference

Guided Therapeutics Reports Third Quarter 2015 Financial Results

New Nigerian Minister of Health is Early Supporter of Guided Therapeutics’ LuViva® Advanced Cervical Scan use in Africa

Guided Therapeutics Schedules Conference Call to Discuss Third Quarter 2015 Financial Results

FDA Grants Guided Therapeutics’ Request for New Meeting Date to Plan Path Forward for LuViva® Advanced Cervical Scan PMA Application

2016 Turkish Ministry of Health Order for Guided Therapeutics’ LuViva® Advanced Cervical Scan Four Times 2015 Projected Revenue

Guided Therapeutics Expands China Rights Negotiations for LuViva® Advanced Cervical Scan to Three Potential Partners

Guided Therapeutics’ Fourth Quarter Orders of LuViva® Advanced Cervical Scan Disposables Triple 2014 Total Sales

Study Finds Guided Therapeutics’ LuViva® Advanced Cervical Scan Can Predict Future Worsening of Precancer

Guided Therapeutics Ships First Four LuViva® Advanced Cervical Scans for $14 million Turkish Ministry of Health Order

Guided Therapeutics to Present at 2015 Aegis Growth Conference

Guided Therapeutics and U.S. FDA Agree on Meeting Date to Plan Path Forward for LuViva® Advanced Cervical Scan Premarket Approval Application

Guided Therapeutics’ Turkish Distributor Doubles Order for LuViva® Advanced Cervical Scan Single-Use Disposables for Turkish Ministry of Health

Guided Therapeutics Announces $550,000 Increase to $4 Million Private Placement and Accelerated Interim Closing

Guided Therapeutics Expands Access of the LuViva® Advanced Cervical Scan into Bulgaria

Guided Therapeutics Expands Access of the LuViva® Advanced Cervical Scan into Costa Rica

Guided Therapeutics Submits Proposal to Kenya to Increase Cervical Cancer Screening Rates – Potential Screening Population of 12 Million Women

Guided Therapeutics Advances LuViva PMA Application with FDA

Guided Therapeutics Reports Second Quarter 2015 Financial Results; Closes $10 Million Deal

Guided Therapeutics Schedules Conference Call to Discuss Second Quarter 2015 Financial Results

Guided Therapeutics’ Distributor Signs New Four-year Deal to Sell $10 Million of LuViva® Advanced Cervical Scans to Turkish Ministry of Health

Guided Therapeutics Announces $4 Million Private Placement

Turkish Ministry of Health Expanding Usage of Guided Therapeutics’ LuViva® Advanced Cervical Scan Driving Significant New Orders

Guided Therapeutics Awarded Multiple Tenders for LuViva® Advanced Cervical Scan Systems from Governments in Bangladesh

FDA Completes Review of Guided Therapeutics’ LuViva® Advanced Cervical Scan PMA Application

Guided Therapeutics Reports First Quarter 2015 Results

County Government of Nairobi, Kenya Purchases Initial LuViva® Advanced Cervical Scan for Cervical Cancer Screening Program

Guided Therapeutics to Report First Quarter 2015 Results and Hold Conference Call; Provide Update on LuViva FDA Timing

Canadian Pilot Programs Initiated with LuViva® Advanced Cervical Scan for Provincial-level Cancer Care Support

Guided Therapeutics Completes Interim Financing; Initiating Distribution of LuViva® Advanced Cervical Scan in China

Guided Therapeutics Ships First Commercial LuViva® Advanced Cervical Scans to Indonesia

Guided Therapeutics Reports 2014 Results

Guided Therapeutics to Report Fourth Quarter 2014 Results and Hold Conference Call; Provide Update on Business Activity

Guided Therapeutics Provides an Update on FDA Review Time for LuViva® Advanced Cervical Scan